Amgen Inc. (AMGN)
277.29
-5.35 (-1.89%)
At close: Apr 17, 2025, 3:59 PM
277.56
0.10%
After-hours: Apr 17, 2025, 07:21 PM EDT
Amgen Revenue Breakdown
| Period Ending | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aranesp Revenue | 337M | 349M | 319M | 323M | 365M | 355M | 348M | 358M | 357M | 358M | 362M | 396M | 367M | 355M | 384M | 387M | 422M | 452M | 436M | 414M | 477M | 472M | 454M |
| Aranesp Revenue Growth | -3.44% | +9.40% | -1.24% | -11.51% | +2.82% | +2.01% | -2.79% | +0.28% | -0.28% | -1.10% | -8.59% | +7.90% | +3.38% | -7.55% | -0.78% | -8.29% | -6.64% | +3.67% | +5.31% | -13.21% | +1.06% | +3.96% | n/a |
| BLINCYTO Revenue | 327M | 244M | 1.01B | 1.03B | 1.07B | 579M | 1.1B | 1.11B | 1.05B | 862M | 1.11B | 1.29B | 1.14B | 924M | 1.32B | 1.25B | 1.15B | 1.37B | 1.36B | 1.15B | 1.29B | 1.3B | 1.1B |
| BLINCYTO Revenue Growth | +34.02% | -75.96% | -1.93% | -3.09% | +84.46% | -47.27% | -0.72% | +5.23% | +21.93% | -22.20% | -14.04% | +12.67% | +23.81% | -30.26% | +6.34% | +8.07% | -15.59% | +0.22% | +18.42% | -10.91% | -0.77% | +17.83% | n/a |
| ENBREL Revenue | 825M | 567M | 350M | 307M | 281M | 254M | 325M | 318M | 317M | 287M | 284M | 293M | 280M | 251M | 260M | 253M | 280M | 266M | 267M | 245M | 532M | 610M | 494M |
| ENBREL Revenue Growth | +45.50% | +62.00% | +14.01% | +9.25% | +10.63% | -21.85% | +2.20% | +0.32% | +10.45% | +1.06% | -3.07% | +4.64% | +11.55% | -3.46% | +2.77% | -9.64% | +5.26% | -0.37% | +8.98% | -53.95% | -12.79% | +23.48% | n/a |
| EVENITY Revenue | 399M | 342M | 386M | 349M | 346M | 358M | 469M | 288M | 284M | 266M | 630M | 609M | 534M | 476M | 538M | 561M | 479M | 630M | 698M | 592M | 433M | 452M | 445M |
| EVENITY Revenue Growth | +16.67% | -11.40% | +10.60% | +0.87% | -3.35% | -23.67% | +62.85% | +1.41% | +6.77% | -57.78% | +3.45% | +14.04% | +12.18% | -11.52% | -4.10% | +17.12% | -23.97% | -9.74% | +17.91% | +36.72% | -4.20% | +1.57% | n/a |
| KRYSTEXXA Revenue | 310M | 235M | 629M | 419M | 310M | 362M | 616M | 627M | 594M | 451M | 873M | 803M | 814M | 758M | 701M | 659M | 654M | 476M | 499M | 471M | n/a | n/a | n/a |
| KRYSTEXXA Revenue Growth | +31.91% | -62.64% | +50.12% | +35.16% | -14.36% | -41.23% | -1.75% | +5.56% | +31.71% | -48.34% | +8.72% | -1.35% | +7.39% | +8.13% | +6.37% | +0.76% | +37.39% | -4.61% | +5.94% | n/a | n/a | n/a | n/a |
| Kyprolis Revenue | 378M | 376M | 1.11B | 567M | 600M | 392M | 992M | 862M | 922M | 852M | 273M | 272M | 286M | 286M | 205M | 200M | 229M | n/a | n/a | n/a | n/a | n/a | n/a |
| Kyprolis Revenue Growth | +0.53% | -66.03% | +95.24% | -5.50% | +53.06% | -60.48% | +15.08% | -6.51% | +8.22% | +212.09% | +0.37% | -4.90% | 0.00% | +39.51% | +2.50% | -12.66% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Nplate Revenue | 456M | 317M | 417M | 986M | 1.03B | 927M | 333M | 309M | 325M | 329M | 545M | 517M | 488M | 468M | 481M | 435M | 481M | n/a | n/a | n/a | n/a | n/a | n/a |
| Nplate Revenue Growth | +43.85% | -23.98% | -57.71% | -4.09% | +10.90% | +178.38% | +7.77% | -4.92% | -1.22% | -39.63% | +5.42% | +5.94% | +4.27% | -2.70% | +10.57% | -9.56% | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Otezla Revenue | 564M | 394M | 527M | 406M | 424M | 388M | 484M | 495M | 533M | 502M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Otezla Revenue Growth | +43.15% | -25.24% | +29.80% | -4.25% | +9.28% | -19.83% | -2.22% | -7.13% | +6.18% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Prolia Revenue | 1.04B | 999M | n/a | 519M | 530M | 536M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Prolia Revenue Growth | +4.60% | n/a | n/a | -2.08% | -1.12% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Repatha (evolocumab) Revenue | 567M | 517M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Repatha (evolocumab) Revenue Growth | +9.67% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEPEZZA Revenue | 488M | 424M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEPEZZA Revenue Growth | +15.09% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEZSPIRE Revenue | 269M | 173M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TEZSPIRE Revenue Growth | +55.49% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vectibix Revenue | 282M | 247M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Vectibix Revenue Growth | +14.17% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| XGEVA Revenue | 541M | 561M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| XGEVA Revenue Growth | -3.57% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Us Revenue | 8.38B | 7.73B | 7.79B | 6.93B | 6.14B | 5.39B | 4.82B | 4.67B | 4.5B | 4.67B | 4.2B | 1.32B |
| Non-Us Revenue Growth | +8.49% | -0.73% | +12.37% | +12.87% | +13.90% | +11.80% | +3.32% | +3.78% | -3.69% | +11.22% | +218.60% | n/a |
| United States Revenue | 19.81B | 18.59B | 18.19B | 18.5B | 17.22B | 18.36B | 18.03B | 18.33B | 17.17B | 15.4B | 14.48B | 3.7B |
| United States Revenue Growth | +6.51% | +2.20% | -1.63% | +7.39% | -6.18% | +1.82% | -1.62% | +6.75% | +11.50% | +6.33% | +291.25% | n/a |
Operating Expense Breakdown
| Period Ending | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.88B | 1.63B | 1.78B | 1.81B | 2.27B | 1.35B | 1.29B | 1.26B | 1.57B | 1.29B | 1.33B | 1.23B | 1.43B | 1.3B | 1.38B | 1.25B | 1.77B | 1.35B | 1.29B | 1.32B | 1.51B | 1.22B | 1.26B | 1.15B | 1.56B | 1.29B | 1.35B | 1.13B | 1.43B | 1.17B | 1.21B | 1.06B | 1.32B | 1.24B | 1.29B | 1.2B | 1.42B | 1.24B | 1.16B | 1.03B |
| Selling, General, and Administrative Revenue Growth | +15.57% | -8.96% | -1.27% | -20.49% | +68.07% | +4.56% | +2.86% | -19.97% | +22.14% | -3.01% | +8.06% | -13.82% | +9.20% | -5.71% | +10.37% | -29.27% | +31.72% | +3.94% | -1.60% | -13.02% | +23.71% | -2.94% | +9.19% | -25.98% | +20.57% | -4.43% | +20.05% | -21.02% | +21.97% | -3.23% | +13.63% | -19.58% | +6.35% | -3.72% | +7.40% | -15.04% | +13.83% | +7.24% | +13.06% | n/a |
| Research and Development Revenue | 1.72B | 1.45B | 1.45B | 1.34B | 1.53B | 1.08B | 1.11B | 1.06B | 1.32B | 1.11B | 1.04B | 959M | 1.35B | 1.42B | 1.08B | 967M | 1.23B | 1.06B | 964M | 952M | 1.31B | 1B | 924M | 879M | 1.18B | 926M | 869M | 760M | 1.04B | 877M | 873M | 769M | 1.08B | 990M | 900M | 872M | 1.09B | 1.12B | 964M | 894M |
| Research and Development Revenue Growth | +18.90% | +0.21% | +7.74% | -12.45% | +42.17% | -3.05% | +5.20% | -20.09% | +19.06% | +7.03% | +8.34% | -28.86% | -5.20% | +31.42% | +11.89% | -21.32% | +15.73% | +10.17% | +1.26% | -27.44% | +31.07% | +8.33% | +5.12% | -25.63% | +27.65% | +6.56% | +14.34% | -27.13% | +18.93% | +0.46% | +13.52% | -28.66% | +8.89% | +10.00% | +3.21% | -20.22% | -2.32% | +16.08% | +7.83% | n/a |